• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "雷帕霉素" 24 results
        • Role of Mitochondria in Apoptosis Induced by Rapamycin of Hepatocellular Carcinoma Bel-7402 Cells

          Objective To investigate the cell growth inhibition and apoptosis induced by rapamycin on human hepatocellular carcinoma Bel-7402 cells and to study the role of mitochondrium membrane potential in the process of apoptosis. Methods Bel-7402 cells in vitro were given 5, 10, 20, 30, 40 and 50 nmol/L different concentrations of rapamycin, and the cell growth inhibiting ratio of Bel-7402 was assessed by MTT assay. The changes of morphology of Bel-7402 were observed by Hoechst 33258 staining and flow cytometry (FCM), respectively; The cell mitochondrial membrane potential was detected by using JC-1 staining method. Results Rapamycin could inhibit the growth of Bel-7402 cells significantly by inducing apoptosis, and the growth suppression and the cell apoptosis both presented time-effect relationship and were also dose-dependent. The rates of inhibiting and cell apoptosis after 72 h exposure to 50 nmol/L rapamycin were significantly higher that those of other groups (P<0.01). Typical morphological changes of cell apoptosis were observed very clearly after the Bel-7402 cells had been exposed to rapamycin for 48 hours using Hoechst 33258 staining method, and it was also observed that the mitochondrial membrane potential decreased when apoptosis occured (P<0.01). Conclusion Rapamycin could inhibit the growth of Bel-7402 cells by inducing cell apoptosis, and the descent of mitochondrial membrane potential may play an important role in the process of cell apoptosis.

          Release date:2016-09-08 11:49 Export PDF Favorites Scan
        • 結節性硬化精準治療與隨訪研究進展

          結節性硬化(Tuberous sclerosis complex,TSC)是一種罕見的常染色體顯性遺傳性病,常在兒童期起病。結節性硬化致病基因是TSC1和TSC2基因,其臨床特點包括癲癇發作、特征性皮膚改變及多系統腫瘤,TSC治療手段主要有抗癲癇發作治療、功能康復治療、TSC相關神經精神異常(Tuberous sclerosis associated neuropsychiatric disorders,TAND)相關的行為治療以及各部位結節的外科手術治療,mTOR抑制劑是該病的精準治療藥物,對腫瘤增長和癲癇發作有顯著的改善作用。該文對近年結節性硬化精準治療與隨訪文獻進行綜述,探討結節性硬化精準治療與隨訪研究的進展。

          Release date:2023-03-13 02:15 Export PDF Favorites Scan
        • The role of mTOR signaling pathway in bleomycin-induced pulmonary fibrosis at mice

          ObjectiveTo investigate the mechanism of mTOR signaling pathway in bleomycin (BLM)-induced pulmonary fibrosis in mice.MethodsSixty C57BL/6 mice were randomly divided into a control group and a BLM group. Pulmonary fibrosis model was induced by single intratracheal instillation of bleomycin (2.5 mg/kg) in the BLM group. Similarly, 0.9% saline was instilled directly into the trachea in the control group. Then all mice were sacrificed at 21 days. The lungs were collected for morphometric analysis with HE and Masson staining. The degree of pulmonary fibrosis was evaluated with Ashcroft score. The activity of mTOR signaling pathway was measured by Western blot. The level of collagen1, collagen3 mRNA was assessed with quantitative real time PCR.ResultsThe thickening alveolar septa, accumulation of inflammatory cells, and fibrous obliteration in the BLM group were exhibited predominantly compared with the control group. There was a significant difference in Ashcroft score between the BLM group and the control (P<0.05). Also, the activity of mTOR signaling pathway was up-regulated and the expression of collagen1 mRNA and collagen3 mRNA was increased in the BLM group.ConclusionAberrant activation of mTOR signaling pathway aggravates the pulmonary fibrogenesis.

          Release date:2018-03-29 03:32 Export PDF Favorites Scan
        • Human umbilical cord mesenchymal stem cell exosomes target miR-126 regulate the expression of vascular endothelial growth factor-A in high glucose-induced human retinal vascular endothelial cells

          ObjectiveTo explore the involvement of miR-126 and the role of mammalian target of rapamycin (mTOR)/hypoxia-induced factor 1 α (HIF-1 α) pathway in regulating human umbilical cord mesenchymal stem cells (hUCMSCs) exosomes (Exo) on vascular endothelial growth factor (VEGF)-A levels in high glucose-induced human retinal vascular endothelial cells (HRECs). MethodsThe hREC was cultured in EGM-2-MV endothelial cell culture medium with 30 mmol/L glucose and placed in hypoxic cell incubator by 1% oxygen concentration. The cell model of high glucose and low oxygen was established. After modeling, divided HRECs into Exo group, phosphate buffer saline (PBS) group, PBS+anti-miR126 group, Exo+anti-miR126 group, PBS+anti-mTOR group, and PBS+anti-HIF-1 α group. High-glucose and hypoxia-induced hREC in the PBS and Exo groups were respectively co-cultured with PBS and 100 μg/ml hUCMSC Exo. PBS+anti-mTOR group, PBS+anti-HIF-1 α group: 500 nmol/L mTOR inhibitor ADZ2014, 25 μmol/L HIF-1 α inhibitor YC-1 pretreatment for hREC 12 h, and then co-culture with PBS after High-glucose and hypoxia-induced. PBS+anti-miR126 group, Exo+anti-miR126 group: miR-126 LNA power inhibitor probe was transfected with high glucose, and co-cultured with PBS and hUCMSC Exo 6 h after transfection. Real-time polymerase chain reaction (qPCR) measured miRNA-126 expression levels in PBS, and Exo groups for 0, 8, 16 and 24 h. After 24 hof co-culture, the levels of mTOR and HIF-1 α in the cells of PBS and Exo groups were detected by immunofluorescence, Western blot and qPCR, respectively. Western blot, qPCR detection of VEGF-A expression levels in cells of the PBS+anti-mTOR and PBS+anti-HIF-1 α groups. The expression of VE GF-A, mTOR, and HIF-1 α mRNA was measured in cells of PBS+anti-miR126 group and Exo+anti-miR126 group by qPCR. Comparison between two groups was performed by t-test; one-way ANOVA was used for comparison between multiple groups. ResultsAt 0, 8, 16 and 24 h, the relative mRNA expression of miR-126 gradually increased in the Exo group (F=95.900, P<0.05). Compared with the PBS group, The mTOR, HIF-1 α protein (t=3.466, 6.804), mRNA in HRECs in the Exo group, VEGF-A mRNA expression (t=8.642, 7.897, 6.099) were all downregulated, the difference was statistically significant (P<0.05). The relative expression level of VEGF-Aprotein (t=3.337, 7.380) and mRNA (t=8.515, 10.400) was decreased in HRECs of the anti-mTOR+PBS group and anti-HIF-1 α+PBS group, differences were statistically significant (P<0.05). The relative expression of VEGF-A, mTOR, and HIF-1 α mRNA was significantly increased in the cells of the Exo+anti-miR126 group, the differences were all statistically significant (t=4.664, 6.136, 6.247; P<0.05). ConclusionsmiR-126 plays a role in regulating the effect of hUCMSCs exosomes on VEGF-A levels in high glucose-induced HRECs via mTOR-HIF-1 α pathway.

          Release date:2024-06-18 11:04 Export PDF Favorites Scan
        • 結節性硬化癥診斷及其相關癲癇的非手術治療

          結節性硬化癥(Tuberous sclerosiscomplex,TSC)是一種罕見的 TSC 基因突變引起的常染色體顯性遺傳性神經皮膚綜合征,可累及皮膚、神經、眼、心肺腎等多器官,臨床表現或基因檢測可以診斷。顱內病變為皮質結節、室管膜下巨細胞星形細胞瘤和鈣化灶,癲癇是其主要的神經系統表現,且與智力損害及神經心理異常密切相關。TSC 相關癲癇的非手術治療包括哺乳動物雷帕霉素靶蛋白抑制劑、抗癲癇藥物和生酮飲食等,但藥物難治性癲癇比率超過 50%;其中 TSC 相關的嬰兒痙攣癥首選氨己烯酸治療。

          Release date:2019-03-21 11:04 Export PDF Favorites Scan
        • Mutiple factors analusis of the influence of epilepsy onset age on the patients with tuberous sclerosis complex

          ObjectiveTo investigate the relationships between the onset age, genotype, clinical phenotype and the efficacy of Rapamycin in patients with tuberous sclerosis complex.MethodsRetrospectively analyze the clinical data of patients with tuberous sclerosis complex (TSC) who were diagnosed with epilepsy in Guangdong Sanjiu Brain Hospital from October 2013 to December 2018. Meanwhile, the relationships between the onset age of epilepsy and genotype, clinical phenotype and Rapamycin efficacy were analyzed comprehensively.ResultsTSC gene was detected in 104 patients with tuberous sclerosis complex, of which 85 (81.7%) were positive and 44 (51.8%) were males as well as 41 (48.2%) were females, with an average age of (4.0±4.9) years old. And there were 34 (40.0%) TSC1 mutations and 51 (60.0%) TSC2 mutations. The patients were divided into 3 groups according to their ages: ≤1 year old, 1 ~ 6 years old and ≥6 years old. Among them, 31 cases (36.5%) were in the ≤1 year old group, 31 cases (36.5%) in the 1 ~ 6 years old group and 23 cases (27.0%) in the ≥6 years old group. Through statistical analysis, we found that the onset age of epilepsy in patients with TSC1 and TSC2 gene mutations was statistically different (χ2=9.030, P=0.011). Further analysis of the relationship between the onset age of epilepsy and other clinical phenotypes showed that there were statistical differences in the probability of mental retardation and spasm seizure in different onset age groups of epilepsy (P<0.05). In addition, patients with epilepsy onset age ≤1 year old are more likely to have renal disease and patients with epilepsy onset age ≥6 years old are more likely to have SEGAs. There was no significant difference between the onset age of epilepsy and the efficacy of Rapamycin (P>0.05).ConclusionTSC2 mutation, mental retardation and spasm seizure are more likely to occur in patients with epilepsy onset age ≤1 year old. The study on multiple factors of epilepsy onset age may have a certain guiding role in judging the development and prognosis of TSC with epilepsy.

          Release date:2020-07-20 08:13 Export PDF Favorites Scan
        • 局灶性皮質發育不良的病理機制

          局灶性皮質發育不良(Focal cortical dysplasias, FCDs)是兒童難治性癲癇的常見病因,也是常需癲癇手術的原因。盡管近年來在細胞和分子生物上的進展,FCDs的病理機制仍不清楚。該研究旨在回顧FCDs的分子機制,系統地檢索FCDs組織、分子和電生理方面的文獻,以明確可能的治療靶點。哺乳動物雷帕霉素靶蛋白信號通路(mammalian target of rapamycin,mTOR)是一些FCDs結構和電生理紊亂的重要機制。其他的假說包括病毒感染、早產、頭部外傷和腦腫瘤。mTOR抑制劑(如:雷帕霉素)在動物和少量FCDs患者的隊列癲癇控制中取得陽性結果。近期研究在發育不良組織細胞的分子和電生理機制方面取得了令人鼓舞的進展。盡管mTOR抑制劑有良好的治療前景,但仍需大規模的隨機對照研究評估其有效性和不良反應,并且需要基礎研究發現新的分子水平診斷和治療方式。

          Release date:2016-11-28 01:27 Export PDF Favorites Scan
        • mTOR抑制劑抑制皮質發育不良小鼠癲癇發作

          哺乳動物雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)在皮質發育不良(Cortical dysplasia, CD)及癲癇動物模型中超活化。在神經元特異性Pten基因敲除(Neuronsubset-specific Pten knockout, NS-Pten KO)小鼠模型中, 盡管在早期癲癇發生過程中抑制mTOR信號通路能夠減少癲癇樣活動, 但mTOR抑制劑在癲癇建立后的作用尚不清楚。文章通過建立伴有嚴重慢性癲癇的NS-Pten KO成年小鼠模型, 探究mTOR抑制劑對其癲癇樣活動和其他神經病理的作用。NS-Pten KO小鼠癲癇樣活動、mTOR信號通路的異常調節和相關神經病理隨年齡增長的變化通過視頻腦電(video-electroencephalography, VEEG), 蛋白免疫印跡和免疫組化檢測。NS-Pten KO小鼠出生后9周開始接受mTOR抑制劑雷帕霉素治療(10 mg/kg i.p, 5d/周)并采用VEEG監測癲癇樣活動。通過蛋白免疫印跡和免疫組化檢測雷帕霉素的作用。試驗發現, 隨著年齡增長, NS-Pten KO小鼠的癲癇樣活動惡化, 同時伴有mTOR復合物1和2(mTOR complex 1 and 2, mTORC1 and mTORC2)調節異常和進展性的星形膠質細胞和小膠質細胞增生。雷帕霉素治療抑制癲癇樣活動, 改善基線腦電活動并提高嚴重癲癇NS-PtenKO小鼠的預后。在分子水平, 雷帕霉素治療降低mTORC1和mTORC2水平并減少星形膠質細胞和小膠質細胞增生。研究表明在NS-Pten KO小鼠中, 雷帕霉素成功治療癲癇有較寬的時間窗。抑制mTOR可能是CD伴慢性癲癇及mTOR信號通路基因調節異常的潛在治療手段。

          Release date:2017-01-22 09:09 Export PDF Favorites Scan
        • Progress of mTOR Signal Pathway in Chemo-Resistance of Gastric Cancer

          Objective To review the role of mTOR signal pathway in chemo-resistance of gastric cancer. Methods Domestic and international publications related mTOR signal pathway in chemo-resistance of gastric cancer in recent years were collected and reviewed. Results mTOR was a central signaling molecule of mTOR signal pathway, which regulated key cellular processes such as cell growth, cell proliferation, cell metabolism, and angiogenesis. Signaling molecules of mTOR signal pathway were overexpressed in gastric cancer. Moreover, mTOR signal pathway might play an important role in chemo-resistance of gastric cancer, and tumor stem cells were involved in it too. Conclusion As mTOR signal pathway plays an important role in chemo-resistance of gastric cancer, the combination of mTOR inhibitors and chemotherapy drugs may overcome the chemo-resistance of gastric cancer.

          Release date: Export PDF Favorites Scan
        • Clinical observation of rapamycin in the treatment of tuberous sclerosis complicated with refractory epilepsy

          ObjectiveTo analyze the clinical efficacy and safety of rapamycin in the treatment of Tuberous sclerosis complex ( TSC ) complicated with refractory epilepsy, and to provide scientific basis for the clinical treatment of this disease.MethodsRetrospective analysis was performed on 22 children with TSC complicated with refractory epilepsy admitted to Henan People's Hospital from 2017 to 2019, including 11 males and 11 females who met the inclusion criteria, with an average age of (27.91±36.92) months. They were treated with antiepileptic drugs and rapamycin at the same time, and followed up for at least 1 year.To observe the change of seizure frequency before and after treatment with rapamycin.ResultsThe mean reduction rate of seizure frequency in children with tuberous sclerosis complicated with refractory epilepsy was 52.1% 6 months after the addition of rapamycin, and 51.2% 12 months after the addition of rapamycin. The number of seizure-free days could be maintained. The difference before and after the addition of rapamycin was statistically significant (P<0.05).ConclusionThe addition of rapamycin in the treatment of TSC complicated with refractory epilepsy can reduce the frequency of seizure and increase the number of days without seizure, and the adverse reactions are mild/moderate. Rapamycin has certain safety in children with regular follow-up.

          Release date:2021-10-25 01:58 Export PDF Favorites Scan
        3 pages Previous 1 2 3 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜